A Clinical Study of Iparomlimab and Tuvonralimab Combined With Bevacizumab and Alternating Triweekly CAPOX/mCAPIRI Regimen as First-line Treatment for Unresectable Advanced Colorectal Cancer

Prior treatment

• 1\. Prior hypersensitivity to any of the study drugs;

Other illness

• 2\. Active or known or suspected autoimmune disease requiring systemic treatment, including but not limited to autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism, thyroid dysfunction, asthma requiring bronchodilator intervention;
• 5\. Uncontrolled symptomatic brain metastases or psychiatric disorders preventing accurate expression of subjective symptoms;
• 6\. Vital organ function failure;
• 7\. Conditions affecting drug absorption/distribution/metabolism/excretion (e.g., seizures, central nervous system diseases, cognitive impairment due to psychiatric disorders, chronic diarrhea, cachexia, etc.);
• 9\. History of severe cardiac disease (including congestive heart failure, uncontrolled high-risk arrhythmia, angina requiring medication, definite valvular heart disease history, severe myocardial infarction, refractory hypertension);
• 10\. Active infection requiring systemic treatment;
• 11\. Known history of HIV infection;
• 12\. Known history of hepatitis B or active hepatitis C virus infection;
• 13\. Other conditions deemed unsuitable for enrollment by the investigator.

Other

• 3\. Presence of non-measurable lesions (e.g., pleural effusion/ascites, carcinomatous lymphangitis, diffuse liver involvement, bone metastases);
• 4\. Pregnant or lactating women;
• 8\. Patients with complete or incomplete intestinal obstruction;

• 1\. Age 18-75 years;
• 2\. Patients with histologically or cytologically confirmed unresectable, advanced colorectal cancer;
• 3\. No prior systemic treatment;
• 4\. ECOG PS score ≤2;
• 5\. Expected survival ≥3 months;
• 6\. MSS/MSI-L status;
• 7\. At least one evaluable lesion based on RECIST 1.1 criteria;
• 8\. No prior systemic chemotherapy or other systemic therapy, or only received adjuvant chemotherapy with disease progression or recurrence within 6 months after completion of treatment;
• 9\. Adequate organ function reserve, with specific hepatic, renal, and hematologic parameters as follows:
  • White blood cell count ≥3.5×10⁹/L
  • Absolute neutrophil count ≥1.5×10⁹/L
  • Hemoglobin ≥100 g/L
  • Platelets ≥80×10⁹/L
  • Serum liver enzymes ≤2.5× upper limit of normal (ULN) in patients without liver metastases
  • Serum liver enzymes ≤5× ULN in patients with liver metastases
  • Serum bilirubin ≤1.5× ULN
  • Serum creatinine ≤1.5× ULN
• 10\. No history of other malignancies;
• 11\. Voluntary participation in this study with signed informed consent.